2-(4-Bromophenyl)-6-methylpyrazolo[1,5-a]pyrimidine | 934329-27-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-Bromophenyl)-6-methylpyrazolo[1,5-a]pyrimidine
• CAS: 934329-27-8
• 化学式: C₁₃H₁₀BrN₃
• 分子量: 288.147
• InChiKey: KHBDZOISBUHLLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• INHIBITORS OF HEPATITIS C VIRUS POLYMERASE
  申请人：Lee Sam SK

  公开号：US20120183496A1

  公开（公告）日：2012-07-19

  The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R 1A , R 1B , R 2 , and R 3 are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.
• Inhibitors of Hepatitis C Virus Polymerase
  申请人：COCRYSTAL DISCOVERY, INC.

  公开号：US20170273962A1

  公开（公告）日：2017-09-28

  The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R 2 , and R 3 are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.
• US8771665B2
  申请人：——

  公开号：US8771665B2

  公开（公告）日：2014-07-08
• US9707215B2
  申请人：——

  公开号：US9707215B2

  公开（公告）日：2017-07-18
• [EN] 4-CARBOXY PYRAZOLE DERIVATIVES AS ANTI-VIRAL AGENTS<br/>[FR] DERIVES DE 4-CARBOXY PYRAZOLE UTILISES EN TANT QU'AGENTS ANTIVIRAUX
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2007039146A1

  公开（公告）日：2007-04-12

  [EN] Anti-viral agents of compounds of Formula (I): wherein A, R¹, R², R³ and R⁴ are as defined in the specification, processes for their preparation and their use in HCV treatment are provided.
  [FR] L'invention concerne des agents antiviraux constitués de composés de formule (I) dans laquelle A, R¹, R², R³ et R⁴ sont tels que définis dans la description. La présente invention se rapporte en outre à leurs procédés de préparation, et à leur utilisation pour traiter les infections par le virus de l'hépatite C (HCV).